S&P 500   3,832.51 (-0.23%)
DOW   30,837.73 (-0.51%)
QQQ   325.20 (-0.07%)
AAPL   141.56 (+1.79%)
MSFT   226.13 (+0.08%)
FB   275.06 (+0.20%)
GOOGL   1,865.84 (-1.41%)
AMZN   3,283.82 (-0.26%)
TSLA   862.43 (+1.87%)
NVDA   536.72 (-2.15%)
BABA   259.60 (+0.38%)
CGC   32.64 (-3.43%)
GE   10.89 (-1.98%)
MU   79.67 (-3.17%)
AMD   92.86 (+0.08%)
NIO   59.99 (-3.16%)
T   28.78 (-0.52%)
F   11.02 (-4.34%)
ACB   10.16 (-4.60%)
BA   200.61 (-2.54%)
DIS   170.36 (-1.40%)
NFLX   555.03 (-1.79%)
GILD   67.00 (+0.09%)
S&P 500   3,832.51 (-0.23%)
DOW   30,837.73 (-0.51%)
QQQ   325.20 (-0.07%)
AAPL   141.56 (+1.79%)
MSFT   226.13 (+0.08%)
FB   275.06 (+0.20%)
GOOGL   1,865.84 (-1.41%)
AMZN   3,283.82 (-0.26%)
TSLA   862.43 (+1.87%)
NVDA   536.72 (-2.15%)
BABA   259.60 (+0.38%)
CGC   32.64 (-3.43%)
GE   10.89 (-1.98%)
MU   79.67 (-3.17%)
AMD   92.86 (+0.08%)
NIO   59.99 (-3.16%)
T   28.78 (-0.52%)
F   11.02 (-4.34%)
ACB   10.16 (-4.60%)
BA   200.61 (-2.54%)
DIS   170.36 (-1.40%)
NFLX   555.03 (-1.79%)
GILD   67.00 (+0.09%)
S&P 500   3,832.51 (-0.23%)
DOW   30,837.73 (-0.51%)
QQQ   325.20 (-0.07%)
AAPL   141.56 (+1.79%)
MSFT   226.13 (+0.08%)
FB   275.06 (+0.20%)
GOOGL   1,865.84 (-1.41%)
AMZN   3,283.82 (-0.26%)
TSLA   862.43 (+1.87%)
NVDA   536.72 (-2.15%)
BABA   259.60 (+0.38%)
CGC   32.64 (-3.43%)
GE   10.89 (-1.98%)
MU   79.67 (-3.17%)
AMD   92.86 (+0.08%)
NIO   59.99 (-3.16%)
T   28.78 (-0.52%)
F   11.02 (-4.34%)
ACB   10.16 (-4.60%)
BA   200.61 (-2.54%)
DIS   170.36 (-1.40%)
NFLX   555.03 (-1.79%)
GILD   67.00 (+0.09%)
S&P 500   3,832.51 (-0.23%)
DOW   30,837.73 (-0.51%)
QQQ   325.20 (-0.07%)
AAPL   141.56 (+1.79%)
MSFT   226.13 (+0.08%)
FB   275.06 (+0.20%)
GOOGL   1,865.84 (-1.41%)
AMZN   3,283.82 (-0.26%)
TSLA   862.43 (+1.87%)
NVDA   536.72 (-2.15%)
BABA   259.60 (+0.38%)
CGC   32.64 (-3.43%)
GE   10.89 (-1.98%)
MU   79.67 (-3.17%)
AMD   92.86 (+0.08%)
NIO   59.99 (-3.16%)
T   28.78 (-0.52%)
F   11.02 (-4.34%)
ACB   10.16 (-4.60%)
BA   200.61 (-2.54%)
DIS   170.36 (-1.40%)
NFLX   555.03 (-1.79%)
GILD   67.00 (+0.09%)
Log in
OTCMKTS:NMUS

Nemus Bioscience Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
$0.03
MA: $0.13▼
$0.65
52-Week Range N/A
Volume1.00 million shs
Average Volume377,395 shs
Market Capitalization$12.05 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.04
Nemus Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics. The company's product candidates in preclinical stage include NB1111 for the treatment of glaucoma; NB1222 used for treating chemotherapy induced nausea and vomiting; and NB3111 for the treatment of methicillin-resistant staphylococcus aureus. Its products under research comprise NB2111 for use in treating chemotherapy induced peripheral neuropathy; and NB2222 for the treatment of uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. Nemus Bioscience, Inc. has a license agreement with the University of Mississippi to research, develop, and commercialize products for the treatment of infectious diseases. The company was founded in 2012 and is headquartered in Costa Mesa, California.

MarketRank™

Overall MarketRank™

0.64 out of 5 stars

Medical Sector

1269th out of 1,923 stocks

Pharmaceutical Preparations Industry

577th out of 773 stocks

Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryCannabis
SectorMedical
Current SymbolOTCMKTS:NMUS
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.nemusbioscience.com
Phone949-396-0330
EmployeesN/A
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio0.12
Quick Ratio0.12

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.12) per share
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-19,190,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-924.42%

Miscellaneous

Outstanding Shares133,908,000
Market Cap$12.05 million
Next Earnings DateN/A
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive NMUS News and Ratings via Email

Sign-up to receive the latest news and ratings for NMUS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Nemus Bioscience (OTCMKTS:NMUS) Frequently Asked Questions

What stocks does MarketBeat like better than Nemus Bioscience?

Wall Street analysts have given Nemus Bioscience a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Nemus Bioscience wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Nemus Bioscience's earnings last quarter?

Nemus Bioscience Inc (OTCMKTS:NMUS) announced its quarterly earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter.
View Nemus Bioscience's earnings history.

Who are some of Nemus Bioscience's key competitors?

Some companies that are related to Nemus Bioscience include Canopy Growth (WEED), Innovative Industrial Properties (IIPR), MedReleaf Corp. (LEAF.TO) (LEAF), GrowGeneration (GRWG), OrganiGram Holdings Inc. (OGI.TO) (OGI), 22nd Century Group (XXII), Emblem (EMC), Bioventix PLC (BVXP.L) (BVXP), ICC Labs Inc. (ICC.V) (ICC), KushCo (KSHB), General Cannabis (CANN), Terra Tech (TRTC), Grow Capital (GRWC), Leafbuyer Technologies (LBUY) and NSAV (NSAV).
View all of NMUS's competitors.

What other stocks do shareholders of Nemus Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nemus Bioscience investors own include (CGC), Emerald Health Therapeutics (EMHTF), KushCo (KSHB), MedMen Enterprises (MMNFF), Aurora Cannabis (ACBFF), CannaRoyalty (ORHOF), Terra Tech (TRTC), 22nd Century Group (XXII), BOTS (MCIG) and Cronos Group (CRON).

Who are Nemus Bioscience's key executives?

Nemus Bioscience's management team includes the following people:
  • Dr. Brian S. Murphy, CEO, Chief Medical Officer & Director (Age 61)
  • Dr. Avtar S. Dhillon, Exec. Chairman (Age 57)
  • Mr. Douglas A. Cesario, Chief Financial Officer (Age 44)
  • Ms. Wendy Cunning, VP of Bus. Operations

What is Nemus Bioscience's stock symbol?

Nemus Bioscience trades on the OTCMKTS under the ticker symbol "NMUS."

How do I buy shares of Nemus Bioscience?

Shares of NMUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is Nemus Bioscience?

Nemus Bioscience has a market capitalization of $0.00.

What is Nemus Bioscience's official website?

The official website for Nemus Bioscience is www.nemusbioscience.com.

How can I contact Nemus Bioscience?

Nemus Bioscience's mailing address is 130 NORTH MARINA DRIVE, LONG BEACH CA, 90803. The biopharmaceutical company can be reached via phone at 949-396-0330.

This page was last updated on 1/25/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.